MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes
Poster 813; PS 068 Improved post-prandial blood glucose excursions with Technosphere inhaled insulin compared to aspart in adult patients with type 1 diabetes: STAT study intention to treat analysis
Poster 677; PS 051 Improved time-in-range on continuous glucose monitor with Technosphere insulin compared to insulin aspart in adults with type 1 diabetes: STAT study per protocol analysis
“We continue to advance the understanding of the potential clinical benefits of Afrezza by sharing the positive data from the STAT study at the 2018 EASD conference,” said
Afrezza STAT Study Poster Presentations at EASD
|Title:||Improved Post-prandial Blood Glucose Excursions with Technosphere Inhaled Insulin Compared to Aspart in Adult Patients with Type 1 Diabetes: STAT Study Intention to Treat Analysis (poster 813; PS 068)|
|Presenter:||Halis K. Akturk, M.D.|
|Conclusion:||Afrezza, when administered at the beginning of a meal, and supplemented at appropriate post meal intervals as needed, significantly improved PPGE and improved TIR when compared with insulin aspart in adult patients with type 1 diabetes.|
|Title:||Improved Time-in-Range on Continuous Glucose Monitor with Technosphere Insulin Compared to Insulin Aspart in Adults with Type 1 Diabetes: STAT study Per Protocol Analysis (poster 677; PS 051)|
|Presenter:||Janet Snell-Bergeon, Ph.D.|
|Conclusion:||The use of Afrezza, with proper supplemental dosing per protocol, significantly improved 24 hour TIR and lowered PPGE (1-4 hours) when compared to insulin aspart. In addition, these data suggest that Afrezza can reduce time in hypoglycemia in adult patients with type 1 diabetes when compared to aspart.|
“We are very pleased to have the opportunity to present results of the STAT study at EASD,” said
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration. Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels. For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
SVP, Investor Relations